While the telemedicine trend continues to grow, we are still reminded by the COVID-19 virus ravaging throughout the world that having the capabilities to remotely care for patients is an actual necessity. A way to keep our front line medical workers just a little more out of harm’s way, while also adding yet another technological superiority that more efficiently prioritizes patients in an already chaotic situation.

As of today (Tuesday), CLEW Medical’s ICU predictive analytics platform, CLEWICU, has received an Emergency Use Authorization (EUA) from the FDA, making the solution the only approved device for monitoring and early detection of respiratory failure and hemodynamic complications, both being reported as common side effects of the COVID-19 virus. The company uses AI-based algorithms and machine learning models, trained on over 100,000 ICU test cases, to remotely assist ICU teams to better manage the unit, predict medical complications hours beforehand, while also efficiently prioritizing patient care. Of course, it also provides added value to medical teams allowing for minimal contact with infected patients.

The company’s monitoring system has already been integrated into a number of U.S. hospitals, currently as a pilot. While also featuring in hospitals in Israel, that have a real need right now for remote monitoring and patient prioritizing following the virus pandemic. Also allowing hospitals to better cope with overcrowded ICU units.

“Healthcare providers need more than just simple analytics. Systems need to be integrated into the provider’s workflow, so as to offer easy use and accessible data. The CLEWICU platform is designed to enable healthcare providers to monitor patient predicted risk levels across all units in real-time, allowing for smart decision making regarding clinical resource allocation, as well as ensuring prompt, proactive, and efficient patient care,” explains co-founder and CEO, Gal Salomon.

The company was founded in 2014 by Gal Salomon and Avigdor Faians. CLEW Medical is based out of Netanya, Israel, and just in January received a $10 million investment, bringing their total raised funds to $20 million up to date.